1 / 11

September 14

Navigo™ and SmartBx™. Prostate Smart Biopsy solutions Enabling tools for Active Surveillance and Focal therapy of Prostate cancer. UC Care Ltd. Proprietary. September 14. 1. Navigo™ System by UC-Care. The Navigo™ is a high accuracy Biopsy system enabling:

warren
Download Presentation

September 14

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Navigo™ and SmartBx™ Prostate Smart Biopsy solutions Enabling tools forActive Surveillance and Focal therapy ofProstate cancer UC Care Ltd. Proprietary September 14 1

  2. Navigo™ System by UC-Care The Navigo™ is a high accuracy Biopsy system enabling: • 3D real-time biopsy navigation and recording • Improved PCa detection • Accurate Active Surveillance (AS) • Planning of focal therapy UC Care Ltd. Proprietary September 14 2

  3. The Navigo™- Technical Capabilities Accurate positioning based on an advanced “local GPS” Insensitive to patient’s movements (critical in non-anesthetized patients) Providing a 3D model of the prostate (based on 2D US) Real-time monitoring of biopsy needle image on 3D model Registration of previous and current procedures (“return to point”) Connects to existing ultrasound systems (End fire, Side fire) Archiving the ultrasound images, biopsies location on the 3D model and pathology reports (recording of the entire procedure) Providing data management solutions Offline/office playback capabilities Patient report including biopsies location on the 3D model Minimal change to current biopsy setup UC Care Ltd. Proprietary September 14 3

  4. The Navigo™ Clinical benefits Requires no change in current TR biopsy procedure Real time monitoring of previously taken biopsies alongside current trajectory, enabling systematic distribution Real time monitoring of needle trajectory location from different points of view Enabling biopsy taken from ROI No lost Data, accumulation of data from sequential Transrectal procedures (accumulated saturated biopsy) In-office planning, and data management capabilities ( for repeat Bxs, treatment) Complete procedure recording Minimal training UC Care Ltd. Proprietary September 14 4

  5. Navigo System™ 3D model of the prostate with biopsy location UC Care Ltd. Proprietary September 14 5

  6. SmartBx™- Specimen treatment Problems & challenges: Detection reduced by: - Small fragments may be lost - Not-in-plane cutting of specimen - Multiple core entanglement Cancer localization - Head- tail orientation - Short cores location (core may be much shorter than needle notch). - Location of cancer within the core Biopsy cores entangled in a paraffin block using current methods UC Care Ltd. Proprietary September 14 6

  7. SmartBx™ solution • The core is directly downloaded on a cassette , preserving the specimen location and orientation as on the needle notch • Several cores may be separately placed, in parallel on the same plane, in a cassette (noentanglement) • The specimens on the cassette is there-on handled by the regular pathology lab process. ( Fixation, Paraffin blocking, etc.) • The SmartBx™ solution advantages • - Simple handling • - Potentially Improved detection (the entire volume is kept) • - Accurate localization for detected cancer within specimen UC Care Ltd. Proprietary September 14 7

  8. SmartBx™ The SmartBx™ solution – summery: • Semi-automated collection of the specimen. • Collection of the entire core volume including fragments. • Straightened cores with minimal distortion. • Compatible and integrated into current routine Path-lab. Process. • In-specimen P.Ca location • Registry of biopsy numbering , Cancer location , pathologic features. UC Care Ltd. Proprietary September 14 8

  9. Clinical advantage Improved PCa detection • Improved detection of clinically significant PCa on 1st biopsy due to better spatial biopsies distribution and SmartBx™ • Improved detection of clinically significant PCa on repeated biopsy due to data from previous sessions and SmartBx™ • Providing the tools needs for Active Surveillance • Reducing number of biopsies (procedures and cores) Saturation biopsy performance achieved by accumulation of standard biopsies data UC Care Ltd. Proprietary September 14 9

  10. Lost Data • Study performed for detecting PCa in patients having high PSA • Prostate biopsy: who, how and when. Can J Urol. 2005 Feb; Djavan B • Cancer detection rates on first, second, third and fourth biopsy were – • 22% (231/1051), 10% (83/820), 5% (36/737) and 4% (4/94), respectively • Calculation of lost data in repeat biopsy procedures: • Total number of Bx procedures performed: 2702 • Total number of procedures without P.Ca. detection (i.e.- were data is not available for repeated Bx) : 2258 - In more than 83% of procedures the data from previous procedures cannot be used to guide the new biopsies - Per each session, the non-accumulated data loss is 78%,90%, 95%, and 96% ( 1st to 4th procedures, in correlation) The Navigo™ saves the biopsy data for future reference and use UC Care Ltd. Proprietary September 14 10

  11. THANK YOU UC Care Ltd. Proprietary September 14 11

More Related